Division of Endocrinology, Diabetes and Metabolism, Virginia Commonwealth University Health System, Richmond, VA, United States.
Division of Endocrinology, Diabetes and Metabolism, University of Arkansas Medical Center, Little Rock, AR, United States.
Front Endocrinol (Lausanne). 2023 Mar 9;14:1118848. doi: 10.3389/fendo.2023.1118848. eCollection 2023.
About 1 in 10 adults worldwide are estimated to have diabetes mellitus. They are at risk of developing life-threatening complications resulting in reduced quality of life, increased mortality and higher healthcare costs. The ability to prevent or delay type 2 diabetes mellitus (T2DM) by modifying some of its risk factors has been hypothesized for decades. The long and often gradual time-course of increasing dysglycemia prior to diabetes diagnosis suggests that interventions during that period could be effective in preventing T2DM. In addition to lifestyle modifications, certain drugs prevent or slow development of hyperglycemia. Recently, drugs used for obesity management were shown to prevent T2DM. In this review, we discuss various pharmacotherapeutic options for preventing T2DM.
据估计,全球约有 10%的成年人患有糖尿病。他们面临着危及生命的并发症的风险,导致生活质量下降、死亡率增加和医疗保健成本增加。几十年来,人们一直假设通过改变一些危险因素来预防或延迟 2 型糖尿病(T2DM)的发生。在糖尿病诊断前,血糖升高的时间往往很长且逐渐,这表明在此期间进行干预可能对预防 T2DM 有效。除了生活方式的改变,某些药物可以预防或减缓高血糖的发展。最近,用于肥胖症管理的药物被证明可以预防 T2DM。在这篇综述中,我们讨论了预防 T2DM 的各种药物治疗选择。